ImClone/B-MS' Erbitux launched in Canada

3 November 2008

ImClone Systems, which recently agreed to a $6.5 billion takeover from Eli Lilly (Marketletter October 13), has launched Erbitux (cetuximab) in Canada for metastatic colorectal cancer.

US drug major Bristol-Myers Squibb helps market the drug in North America as part of a development alliance and is making the product commercially available through its wholly-owned subsidiary Bristol-Myers Squibb Canada.

The drug is approved by Health Canada for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor-expressing mCRC who are refractory to other irinotecan-based chemotherapy, and as single agent therapy for patients who are intolerant to irinotecan-based chemotherapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight